What You Need to Know About Migraine and Heart Disease

What You Need to Know About Migraine and Heart Disease
Katarina Radovic/Stocksy; Yaroslav Danylchenko/Stocksy
Migraine is a neurovascular condition, meaning it involves both the nervous system and blood vessels.

Growing evidence suggests migraine is a risk factor for heart disease. However, the increase in risk for developing heart disease is likely minimal for people with migraine, especially for groups such as young women, whose baseline stroke risk is already low.

What Is the Link Between Migraine and Heart Disease?

Migraine comes with higher rates of cardiovascular disease, stroke, atrial fibrillation, metabolic syndrome, heart attack, hypertension, and dyslipidemia, says Jonathan Fialkow, MD, chief of cardiology at Baptist Health Miami Cardiac and Vascular Institute in Miami.

“The connection isn’t entirely understood, but we do have some strong theories,” says Heather Shenkman, MD, a board-certified interventional cardiologist in Tarzana, California, and 1MD Nutrition Advisory Board member.

“One big factor is the way migraine affects blood vessels,” says Dr. Shenkman. Because migraine often comes with vascular instability — meaning blood vessels can suddenly tighten or widen — the risk of clots, inflammation, and arterial damage can increase over time, she explains.

People with migraine also have higher levels of inflammatory markers, which can contribute to plaque buildup in the arteries, a major heart disease risk factor, says Shenkman.

Migraine and heart disease could also stem from the same lifestyle and genetic risk factors, says Dr. Fialkow.

The QRISK3 calculator, which predicts a person’s 10-year cardiovascular risk, includes all subtypes of migraine as a heart disease risk factor. It estimates that migraine involves a 36 percent higher risk for women, and a 29 percent higher risk for men. Migraine with aura, in particular, could mark a higher risk of heart disease, especially atrial fibrillation.

Stroke and Migraine

A stroke is a life-threatening condition that occurs when blood flow is cut off from the brain.

Health professionals may misdiagnose migraine as a stroke because aura symptoms — which typically involve vision or sensory changes such as numbness or tingling, and less commonly speech, language, cognitive, and vestibular symptoms before the headache starts — can mimic the visual and sensory changes of the other less common migraine-associated neurological symptoms associated with stroke.

While the symptoms of stroke and migraine with aura can be similar, migraine may also point to a higher risk of having a stroke, particularly ischemic stroke, which is caused by blood clots.

 Women with migraine have double the risk of ischemic stroke compared with men.

The link between stroke and migraine is complex, because having a stroke can also cause people with no history of migraine to start experiencing migraine attacks.

Researchers suggest this connection could have to do with genetic mutations that affect brain pathways involved with both migraine and stroke, as well as hormone fluctuations, especially involving estrogen.

If you experience any new aura symptoms, especially visual symptoms, numbness, or weakness, it’s important to seek prompt medical evaluation to rule out serious medical events like stroke.

Patent Foramen Ovale and Migraine

People with migraine are more likely to have a hole between the atria, the right and left upper chambers of the heart, called a patent foramen ovale (PFO).

 This hole closes up for most people a few months after birth, but it stays open in about 25 percent of people.

 Because PFOs are symptomless, most people don’t know they have one.
PFOs may be present in 30 to 50 percent of people who have migraine with aura. Migraine is also more prevalent in people with PFOs.

Although controversial, it has been suggested that surgically closing a PFO may reduce the number of migraine days in some people, particularly those who have migraine with aura.

A systematic review and meta-analysis found that people who had a PFO closure had fewer monthly migraine attacks and migraine days per month after the procedure. However, the surgery’s ability to do away with migraine completely was limited.

PFO closure isn’t necessarily more effective than other medical therapies for migraine, says Fialkow. “More research is needed before definitive PFO closure for migraine relief can be offered,” he says. For now, migraine patients should not be having their PFO closed unless they have a stroke that's likely to be from the PFO's contribution.

Postural Tachycardia Syndrome and Migraine

Migraine is the most common co-occurring condition for people with postural orthostatic tachycardia syndrome (POTS), a condition that causes the heart rate to increase when a person stands up, while blood pressure typically stays the same.

A research review found that 36.8 percent of people with POTS also had migraine.

“The link between the two likely comes down to autonomic dysfunction, meaning the nervous system isn’t regulating blood vessel tone properly,” says Shenkman. “In POTS, blood pools in the lower extremities when standing, causing reduced blood flow to the brian. Because the brain is sensitive to changes in blood flow, this could cause migraine attacks.”

Some research suggests that when a migraine attack activates a person’s stress response, it could intensify vascular dysfunction, worsening POTS symptoms.

Triptan Safety for People With Heart Disease

Triptans, a class of popular anti-migraine medication, work by constricting blood vessels. Because of this, they are not advised for anyone with a condition affecting the heart or blood vessels.

A study investigating triptans’ effects on cardiovascular health found that out of 429,612 people, 11 (0.003 percent of participants) experienced a heart attack and 18 (0.004 percent of participants) had an ischemic stroke with their first triptan prescription.

 Because triptans may pose a slightly higher risk of heart disease, the U.S. Food and Drug Administration (FDA) advises against taking them if you have a history of stroke or coronary artery disease (CAD). The actual data on increased triptan risk for cardiovascular events is considered by several migraine experts as not convincing
Other treatment options exist if you have migraine and a high overall risk for heart disease:

  • Beta-blockers can lower blood pressure and prevent migraine attacks, so these medications are safer for people with a high heart disease risk profile.
  • Topiramate is a seizure prevention medication that can also prevent migraine attacks. While effective, it may have a higher rate of side effects.
  • Statins, a cholesterol-lowering class of medication, show promise in preventing migraine attacks, but more research is needed to confirm this.

Reducing Your Risk of Heart Disease if You Have Migraine

The overall lifetime risk of heart disease is still low for most people with migraine, but it’s a sign to take extra steps to care for your heart, says Shenkman.

The role of estrogen in the higher risk of ischemic stroke for women who experience migraine with aura means that it may be necessary to take precautions around hormonal birth control or hormone therapy.

It’s a good idea to talk with your doctor about headaches and estrogen-based birth control or hormone therapy to evaluate how these could impact your own stroke risk, especially if you’re a woman over age 35 and have migraine with aura.

You might also explore nonhormonal or estrogen-free alternatives to hormonal contraceptives and hormone replacement therapy, like an IUD or antidepressants.

Additionally, you can reduce your overall stroke risk through lifestyle adjustments, including:

  • Maintain a healthy blood pressure by lowering stress and reducing sodium.
  • Manage your cholesterol.
  • Get at least 150 minutes of moderate intensity exercise per week.
  • Avoid smoking and alcohol.
  • Consider alternatives to estrogen-based contraceptives or hormone therapies.
  • Keep up-to-date with any cardiovascular screening your doctor recommends.

“Heart health and migraine management go hand in hand,” says Shenkman. Many of the actions you can take to lower your risk of heart disease may also help prevent migraine attacks, she says.

The Takeaway

  • Migraine, especially with aura, is a risk factor for many types of heart disease, including ischemic stroke.
  • For groups like young women whose baseline risk of stroke is low, having migraine doesn’t raise your overall heart disease risk much.
  • If you experience migraine with aura and have concerns about medications and your overall heart disease risk, talk with your doctor for guidance tailored to your individual health profile.

Resources We Trust

EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Lauinger AR et al. Vascularization, Innervation, and Inflammation: Pathways Connecting the Heart–Brain Axis and Implications in a Clinical Setting. Biomedicines. January 13, 2025.
  2. Valecha J et al. Migraine and heart: A reality check. Global Cardiology Science & Practice. August 1, 2023.
  3. Ravi V et al. Reviewing migraine-associated pathophysiology and its impact on elevated stroke risk. Frontiers in Neurology. August 1, 2024.
  4. Understanding Migraine With Aura. American Migraine Foundation. March 1, 2023.
  5. Zhang S et al. Association between migraine and risk of stroke: a systematic review and meta-analysis. Neurological Sciences. August 1, 2022.
  6. Tekgol Uzuner G et al. Migraine and cardiovascular risk factors: A clinic-based study. Clinical Neurology and Neurosurgery. January 1, 2021.
  7. Cao W et al. The Patent Foramen Ovale and Migraine: Associated Mechanisms and Perspectives from MRI Evidence. Brain Sciences. July 18, 2022.
  8. Patent Foramen Ovale (PFO). American Heart Association. September 26, 2023.
  9. Zhang Y et al. Patent Foramen Ovale Closure for Treating Migraine: A Meta-Analysis. Journal of Interventional Cardiology. February 2, 2022.
  10. Wang Y et al. Association of migraine with patent foramen ovale closure: A systematic review and meta-analysis. IJC Heart & Vasculature. April 1, 2022.
  11. Silalahi TD et al. Efficacy and safety of patent foramen ovale closure for mitigating migraine: a systematic review and meta-analysis of randomized trials and observational studies. Therapeutic Advances in Neurological Disorders. January 2024.
  12. Mueller BR et al. Postural orthostatic tachycardia syndrome and migraine: A narrative review. Headache: The Journal of Head and Face Pain. July 2022.
  13. Ray JC et al. The prevalence of headache disorders in Postural Tachycardia Syndrome: A systematic review and meta-analysis of the literature. Cephalalgia. October 2022.
  14. Mueller B. Episodic Migraine and POTS. Current Pain and Headache Reports. November 1, 2023.
  15. Triptans. The Migraine Trust. December 2024.
  16. Petersen CL et al. Risk of Stroke and Myocardial Infarction Among Initiators of Triptans. JAMA Neurology. February 5, 2024.
  17. Kumar A et al. Migraine Prophylaxis. StatPearls. August 28, 2023.
  18. Frank F et al. CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis. Cephalalgia. October 2021.
  19. Makhlouf HA et al. Exploring the association between statins use or HMG-CoA reductase inhibition and migraine: a systematic review and meta-analysis. The Journal of Headache and Pain. February 3, 2025.
  20. Lyall M et al. Considerations for Contraceptive Use Among Patients with Migraines. Current Obstetrics and Gynecology Reports. June 1, 2023.
  21. Bentivegna E et al. Hormonal therapies in migraine management: current perspectives on patient selection and risk management. Expert Review of Neurotherapeutics. December 2, 2021.
  22. Preventing Stroke. Centers for Disease Control and Prevention. May 15, 2024.
Steven-R-Levine-bio

Steven R. Levine, MD

Medical Reviewer
Steven R. Levine, MD, is a distinguished professor of neurology and emergency medicine and executive vice chairman of neurology at the State University of New York (SUNY). He is also an associate dean for clinical research and faculty development and chief of neurology at the University Hospital of Brooklyn.

After receiving his medical degree at the Medical College of Wisconsin and completing neurology residency at the University of Michigan, he completed a two-year fellowship in cerebrovascular disease and stroke at Henry Ford Health Sciences Center, an NIH Designated Center for Stroke Research in Detroit, where he studied human in vivo magnetic resonance (MR) spectroscopy of the brain during stroke, under the mentorship of K.M.A. Welch, MBChB.

He became involved in acute stroke clinical trials and was one of seven site principal investigators in the NINDS rt-PA Stroke Trial, which led to the first FDA-approved treatment for acute ischemic stroke in 1996. In the 1990s he coined the term “telestroke” in a new concept paper envisioning the use of real-time telemedicine to increase tPA treatment within acute stroke care. Almost 18 years later, telestroke is now part of routine stroke care.

Dr. Levine’s research has been continuously funded by the NIH for over 30 years. He has been active in acute and preventive stroke clinical trials for over 30 years. Levine has mentored over 30 stroke fellows, over 70 residents, and many students and junior faculty. He serves on multiple editorial boards and as a consultant for NIH, AHA-ASA, NSA, and the pharmaceutical industry.

Levine is involved with multiple NIH-NINDS clinical trial networks (NeuroNEXT and StrokeNET) and served as scientific PI (PCORI grant) to develop mobile apps for stroke patients and caregivers. He has been listed in several directories of honors, including Best Doctors in America, America’s Top Doctors, Best Doctors in New York, Best Heart and Stroke Doctors, New York Super Doctors, and U.S. News & World Report Top Doctors. He has received several institutional teaching and mentoring grants (K24, T32, R25) and awards, including the 2017 Alfred Stracher Faculty Recognition Award. Levine has received The C. Miller Fisher, MD, Neuroscience Visionary Award (given annually for “significant contributions to the mission of the American Stroke Association and for clear and lasting contributions to neuroscience”) at The NorthEast Cerebrovascular Consortium (NECC).

Levine is a fellow of the AAN and the AHA Stroke Council, and is an elected member and fellow of the ANA. He has published over 230 peer-reviewed articles (including in The New England Journal of Medicine, JAMA, Circulation, Brain, and Annals of Neurology), 60 invited contributions or reviews, 30 editorials, 50 book chapters, and three books in the field of stroke. He serves on multiple editorial boards (including Stroke as Special Section Editor of Controversies and Debates) and has been a peer reviewer for over 70 journals. He actively attends on the stroke service and sees outpatients in a stroke clinic.
Courtney Telloian

Courtney Telloian

Author

Courtney Telloian is a freelance writer who covers health, psychology, and lifestyle topics. She previously worked as an editor for the mental health brands Psych Central and GoodTherapy. You can find her published work on Healthline, Insider, Psych Central, and GoodTherapy.

In college she minored in Latin, which deepened her passion for language and has made reading dense research papers that much more enjoyable.

Her dedication to accuracy and fine distinctions has come in handy over the years as both a writer and editor, and this is helpful since it makes her annoying in most other settings.